In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer. A gene expression signature associated with sensitivity to ...

ESRD and Treatments May Raise Cancer Risk A single-dose instillation of mitomycin C immediately following therapeutic ureteroscopy upper tract urothelial carcinoma decreased the risk of urothelial ...

In a recent randomized trial, electromotive intravesical administration of mitomycin before transurethral resection was shown to be effective in the prevention of bladder cancer recurrence. Although ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, ...

Despite transurethral resection (TUR) and intravesical instillation of the most effective agents, a proportion of patients with transitional cell carcinoma of the bladder suffer a recurrence of their ...

Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis No significant financial relationships to ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ...

The Food and Drug Administration has approved mitomycin pyelocalyceal (Jelmyto), the first therapy for adults with low-grade upper tract urothelial cancer. "This is the first approval specifically for ...

PRINCETON, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty ...

Gemcitabine delivered via intravesical instillation reduced the risk of recurrence in patients with low-grade non-muscle-invasive urothelial cancer, according to results of a randomized phase III ...

Potential to transform care and access to treatment for this growing patient population PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to ...